Business Context and Reporting Period
Pacific Biosciences of California, Inc. (PACB) filed this Form 8-K on January 12, 2021, to disclose the entry into a Material Definitive Agreement with Invitae Corporation. The filing covers a strategic partnership announced on January 13, 2021, focused on the co-development of a whole genome sequencing platform.
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain audited financial statements, revenue figures, profit margins, cash flow data, or debt levels for the reporting period. The text does not provide a clear value for any historical financial metrics.
Material Changes and Agreement Terms
- Development Program: PACB and Invitae will jointly develop a high-throughput and ultra-high-throughput whole genome sequencing platform ("Program Platform"). The program is expected to last approximately 60 months.
- Cost Reimbursement: Invitae is obligated to reimburse PACB for labor and other development costs incurred under approved budgets. It is expected that Invitae will reimburse substantially all development costs, subject to limitations.
- Preferential Pricing: Upon commercialization, Invitae will receive preferred pricing. For an initial period (up to 4 years from first delivery), Invitae may purchase products at a fixed margin until recouping a mutually agreed multiple of its contribution. A subsequent period (up to 3 years) allows for purchases at a higher margin.
- Most Favored Pricing: During the Preferred Pricing Period, Invitae is entitled to most favored pricing terms.
Outlook, Risks, and Contingencies
- Success Uncertainty: There are no assurances that the development program will be successful or that the Program Platform will be ready for commercial sale.
- Termination Rights: Either party may terminate for material breach. Invitae may also terminate for delays, IP concerns, or if PACB is acquired without consent. Invitae may terminate without cause.
- Financial Contingencies on Termination: Depending on the termination circumstances, PACB may be obligated to refund development costs advanced by Invitae or share future revenue from the Program Platform until Invitae recoups its reimbursed amounts plus an agreed return.
Investor Verification Checklist
- Verify the specific budget caps and limitations on cost reimbursement detailed in the full Development Agreement (Exhibit 10).
- Confirm the "mutually agreed multiple" required for Invitae to recoup its contribution before pricing terms change.
- Review the specific termination clauses regarding asset acquisition and the calculation of potential revenue sharing obligations.
- Monitor future filings for updates on the 60-month development schedule and commercialization milestones.